-
艾媒咨询|2020年中国劳动密集型产业产业布局和市场发展趋势报告
本报告研究涉及企业/品牌/案例:牧原集团、新希望、平潭发展、福建金森、万代服装、长江制衣、绍兴小轩窗布业有限公司、烟台明远家用纺织品有限公司、双驰实业、汕头澄海。
随着国家城镇化加速,农民工供给增速放缓,传统劳动密集型产业面临招工难的问题。特别是随着年轻一代择业观的改变、城镇服务业的高速发展,进城农工偏向选择快递员、餐饮外卖员等当前热门岗位进行就业,这就推动了城镇新型劳动密集型产业的发展。2020年8月7日,中国当前灵活就业从业人员规模达2亿左右,这就为城市新型服务业提供了劳动力基础。
As the country’s urbanization accelerates and the supply of migrant workers has slowed down, traditional labor-intensive industries are facing difficulties in recruiting workers. In particular, with the changes in the young generation's outlook on job selection and the rapid development of urban service industries, rural workers in cities prefer to choose current hot jobs such as couriers and food delivery workers for employment, which promotes the development of new labor-intensive industries in cities and towns. On August 7, 2020, the current number of flexible employment employees in China reached about 200 million, which provides a labor base for the new urban service industry. -
艾媒报告|2019年12月-2020年1月中国医疗器械行业运行及上市公司双月度报告
本报告研究涉及企业/品牌包括:Mavidon,Titan Medical,Aspire Capital Fund,CentriMag,汇桥资本集团,联影医疗技术集团,医达极星,大博医疗,安捷伦,润扬医疗器械,迈瑞医疗,乐普医疗,威高医用,华大基因,安图生物,健帆生物,鱼跃医疗,京东方科技,美亚光电,东软集团,祥生医疗,硕世生物,佰仁医疗,爱博诺德,伟思医疗,安必平,林华医疗,拱东医疗,天智航,三友医疗,赛科希德等。
截至 2020 年 1 月 31 日 24:00,国家卫生健康委员会公布全国确诊病例 11791 例,重症病例 1795 例。短期来看,预计疫情将继续持续一段时间。肺炎疫情期间,病毒检测带动试剂盒需求增加;病毒治疗带动医用设备及医用耗材需求增加。部分医疗器械企业有望构成业绩增厚。
As of 24:00 on January 31, 2020, the National Health Commission announced 11791 confirmed cases and 1795 severe cases. In the short term, the outbreak is expected to continue for some time. During the pneumonia epidemic, virus detection drives demand for kits; virus treatment drives demand for medical equipment and supplies. Some medical device companies are expected to increase their performance. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:恒瑞医药,白云山,111集团,平安好医生,好大夫在线,优健康,春雨医生,微医,丁香医生,和美医疗,北大医疗,PHG,新氧,联合丽格,正广兴家庭医生,强森医疗,微脉,美中嘉和,零氪科技,中有精准医疗,思派网络,普瑞眼科,臻和科技,移宇科技,小鹿医馆,妈咪知道,八百方,京东医药,阿里健康大药房,1药网,一心堂,健一网,好药师,健客网,美丽神器,更美,悦美,美莱整形,伊美尔,丽都整形,芝星整形,欧华美科
大健康产业细分领域的垂直深化,推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响,2019年,大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示,受2018年和2019年上半年医疗领域负面舆情的影响,大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为,受社会医疗需求和国家政策的推动,大健康产业仍是未来投资的亮点。
The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告